Gad Rennert

Gad Rennert

Professor and Chairman, Dept. Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion and Director, Clalit National Cancer Control Center

Address:

7 Michal St.Haifa 34362, Israel

Tel: 972-4-825 0474

Fax: 972-4-834 4358

About the Labratory:

 

Education/training
institution and location  

degree

 

years field of study
University of the Negev, Beer Sheba, Israel

 

University of North Carolina, Chapel Hill, USA

M.D.

 

Ph.D.

1978-1985

 

1986-1988

Medicine

 

Epidemiology/Public Health

My research interests are in molecular/genetic cancer epidemiology, cancer prevention and screening and in molecular or personalized targeted medicine. A particular area of focus of my work has been the interaction between behavioral / environmental risk factors for cancer, and between genetic events (mutations, polymorphisms, variants, gene-expression) in the causation of breast, colorectal, lung, gynecological, pancreato-hepato-biliary and other cancers. Cancer chemoprevention studies are another focus of my scientific work. In addition, I am studying and coordinating the cancer screening activities on a national level in Israel (from policy to implementation-adherence, quality and outcomes), and studying unique founder mutations leading to cancer through the Familial Cancer Consultation Service which cares for thousands of mutation carriers. My work involves a deep epidemiological evaluation of more than 40,000 study participants combined with massive genetic testing using RT-PCR, Sanger sequencing, deep next-generation sequencing, microarray testing, multi-gene expression panels studies, Onco-chip multi-SNP panel, whole exome analysis and other laboratory techniques.

Employment, Positions, Honors

 
1990- Head, Dept. of Epidemiology and Disease Prevention (formerly Department of

Epidemiology and Medical Research), CHS Headquarters, Tel Aviv,

1992-  Chairman, Department of Community Medicine & Epidemiology, Clalit Health Services,

Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion, Haifa, Israel.

1992- Director, CHS National Israeli Cancer Control Center
1992-16 Director, National Israeli Breast Cancer Screening Program. Israeli Ministry of Health
1992- Israeli delegate, Commission of European Communities, Cancer Screening Network (ECN)
1993- Member, National Oncology Council, Israeli Ministry of Health.
1993- Member, International Breast Cancer Screening Network (IBSN) (NCI coordinated).
1993- Chair/member, Ministry of Health – Chief Scientist Committee on Epidemiology.
1994- Member, Managing Board, Israel Cancer Association.
1999-01 Member, Israeli Ministry of Health – Chief Scientist Committee on Research on Cancer.
1998-01 Council member, European Association for Cancer Research.
2000-03 Member, Joint Sub-Committee on Onco-genetics, National Oncology Council and

Gynecology, Obstetrics and Genetics Council, Ministry of Health.

2000-02 Member, Research Committee, National Women’s Health Council, Israeli Ministry of Health
2003- Board member, International Society of Cancer Chemoprevention
 

2004- Member, International Colorectal Cancer Screening Network (ICRCSN) (joint USA-CDC,

Cancer Research UK, American Cancer Society coordination).

2005-16 Director, National Israeli Colorectal Cancer Detection Program. Israeli Ministry of Health
2007- Member, European Society for Medical Oncology (ESMO) Faculty list, Cancer Prevention
2008- Chairman, Committee on 2020 targets in Chronic Disease Control, Israeli Ministry of Health
2009-

 

2013-

Head, Clalit Personalized Medicine  National Program and National Molecular

Medicine Laboratory

Member, Steering Committee, Global Leaders in Genomic Medicine Forum, DC (NIH,

NHGRI, IOM Initiative)

 

Editorial Positions and Boards

Cancer Epidemiology, Biomarkers and Prevention (CEBP), European Journal of Cancer Prevention (associate Editor), European Journal of Radiation Medicine, Disease Markers, Hereditary Cancers in Clinical Practice

Publications (Partial, last 5 years, other significant, out of more than 250):

1.       Dunning AM, Michailidou K, Kuchenbaecker KB, et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016 Feb 29. doi: 10.1038/ng.3521.
2.       Huang R, Wei Y, Hung RJ, et al. Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium.  EBioMedicine. 2015 Sep 24;2(11):1677-1685.
3.       Markowitz SD, Nock NL, Schmit SL, et al.  A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS One. 2016 Jan 11;11(1):e0146435.
4.       Gronwald J, Glass K, Rosen B, et al. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertil Steril. 2016Mar;105(3):781-5.
5.       Meeks HD, Song H, Michailidou K, et al. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2015 Nov 19;108(2).
6.       Lemire M, Qu C, Loo LW, et al. A genome-wide association study for colorectal cancer identifies a risk locus in 14q23.1.  Hum Genet. 2015 Nov;134(11-12):1249-62.
7.       Neter E, Stein N, Rennert G, Hagoel L. Self-rated health is prospectively associated with uptake of screening for the early detection of colorectal cancer, not vice versa. Eur J Cancer Prev. 2015 Jul 30. [Epub ahead of print]
8.       Schumacher FR, Schmit SL, Jiao S, et al. Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nat Commun. 2015 Jul 7;6:7138.
9.       Giordano L, Bisanti L, Salamina G, et al. The EUROMED CANCER network: state-of-art of cancer screening programmes in non-EU Mediterranean countries. Eur J Public Health. 2016 Feb;26(1):83-9.
10.    Gronich N, Deftereos SN, Lavi I, Persidis AS, Abernethy DR, Rennert G. Hypothyroidism is a Risk Factor for New-Onset Diabetes: A Cohort Study. Diabetes Care. 2015 Sep;38(9):1657-64
11.    Manolio TA, Abramowicz M, Al-Mulla F, et al. Global implementation of genomic medicine: We are not alone. Sci Transl Med. 2015 Jun 3;7(290):290ps13.
12.    Saliba W, Barnett-Griness O, Elias M, Rennert G. Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation:a cohort study. J Thromb Haemost. 2015 Nov;13(11):1971-9.
13.    Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2015 May 2. pii: S0090-8258(15)00863-X. [Epub ahead of print]
14.    Blein S, Bardel C, Danjean V, et al. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015 Apr 25;17:61.
15.    Rennert G, Kremer R, Rennert HS, et al. Lower lung cancer rates in Jewish smokers in Israel and the USA. Int J Cancer. 2015 Nov 1;137(9):2155-62.
16.    Blanco I, Kuchenbaecker K, Cuadras D, et al. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One. 2015 Apr 1;10(4):e0120020.
17.    Cremers RG, Eeles RA, Bancroft EK, et al. The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. Urol Oncol. 2015 May;33(5):202.e19-28.
18.    Saliba W, Barnett-Griness O, Elias M, Rennert G. Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: A cohort study. Heart Rhythm. 2015 May;12(5):886-92.
19.    Kuchenbaecker KB, Ramus SJ, Tyrer J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb;47(2):164-71.
20.    Kotsopoulos J, Lubinski J, Gronwald J, et al. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2015 Sep 1;137(5):1136-46.
21.    Saliba W, Barnett-Griness O, Elias M, Rennert G. The association between red cell distribution width and stroke in patients with atrial fibrillation. Am J Med. 2015 Feb;128(2):192.e11-8.
22.    Leitner-Dagan Y, Sevilya Z, Pinchev M, et al. Enzymatic MPG DNA repair assays for two different oxidative DNA lesions reveal associations with increased lung cancer risk. Carcinogenesis. 2014 Dec;35(12):2763-70.
23.    Schmit SL, Gollub J, Shapero MH, Huang SC, Rennert HS, Finn A, Rennert G, Gruber SB. MicroRNA polymorphisms and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):65-72.
24.    Peterlongo P, Chang-Claude J, Moysich KB, et al. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):308-16.
25.    Schmit SL, Schumacher FR, Edlund CK, et al. A novel colorectal cancer risk locus at 4q32.2 identified from an international genome-wide association study. Carcinogenesis. 2014 Nov;35(11):2512-9.
26.    Gronwald J, Robidoux A, Kim-Sing C, et al. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Jul;146(2):421-7.
27.    Saliba W, Barnett-Griness O, Rennert G. Obesity and Association of Serum 25(OH)D Levels with All-Cause Mortality. Calcif Tissue Int. 2014 Sep;95(3):222-8.
28.    Saliba W, Barnett-Griness O, Elias M, Rennert G. Statins use and risk of mortality in patient with Clostridium difficile infection. Clin Microbiol Infect.2014 May 11. doi: 10.1111/1469-0691.12672. [Epub ahead of print]
29.    Shai A, Rennert HS, Rennert G, Sagi S, Leviov M, Lavie O. Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. Gynecol Oncol. 2014;133(2):304-8.
30.    Rennert G, Rennert HS, Pinchev M, Lavie O. The effect of bisphosphonates on the risk of endometrial and ovarian malignancies. Gynecol Oncol. 2014;133(2):309-13.
31.    Bancroft EK, Page EC, Castro E, et al. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. Eur Urol. 2014. pii: S0302-2838(14)0004-9.
32.    Kotsopoulos J, Lubinski J, Moller P, et al.; Hereditary Breast Cancer Clinical Study Group. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat. 2014;143(3):579-86.
33.    Sevilya Z, Leitner-Dagan Y, Pinchev M, Kremer R, Elinger D, Rennert HS, Schechtman E, Freedman LS, Rennert G, Paz-Elizur T, Livneh Z. Low integrated DNA repair score and lung cancer risk. Cancer Prev Res . 2014;4:398-406.
34.    Crous-Bou M, Rennert G, Cuadras D, Salazar R, Cordero D, Saltz Rennert H, Lejbkowicz F, Kopelovich L, Lipkin S, Gruber S, Moreno V. Polymorphisms in alcohol metabolism genes ADH1B and ALDH2, alcohol consumption and colorectal cancer. PLoS One. 2013;8(11):e80158.
35.    Valentini A, Lubinski J, Byrski T, et al. The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2013;142(1):177-85.
36.    Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol. 2013;10(11):625-42.
37.    Lavie O, Pinchev M, Rennert HS, Segev Y, Rennert G. The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol. 2013;130(3):615-9.

 

38.    Couch FJ, Wang X, McGuffog L, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013;9(3):e1003212.
39.    Gaudet MM, Kuchenbaecker KB, Vijai J, et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet. 2013;9(3):e1003173.
40.    European Colorectal Cancer Screening Guidelines Working Group. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45(1):51-9.
41.    Kershenbaum A, Flugelman A, Lejbkowicz F, Arad H, Rennert G. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening. Eur J Cancer. 2013;49(4):923-30.
42. Saliba W, Barnett-Griness O, Rennert G. The relationship between obesity and the increase in serum 25(OH)D levels in response to vitamin D supplementation. Osteoporos Int. 2013;24(4):1447-54.
43. Jakubowska A, Rozkrut D, Antoniou A, et al. Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer 2012;106(12):2016-24.
44. Saliba W, Barnett O, Rennert HS, Rennert G. The risk of all-cause mortality is inversely related to serum 25(OH)D levels. J Clin Endocrinol Metab. 2012;97(8):2792-8.
45. Coté ML, Liu M, Bonassi S, et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer. 2012;48(13):1957-68. 46. Kotsopoulos J, Lubinski J, Salmena L, et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14(2):R42.47. Lejbkowicz F, Cohen I, Barnett-Griness O, Pinchev M, Poynter J, Gruber SB, Rennert G. Common MUTYH mutations and colorectal cancer risk in multiethnic populations. Fam Cancer 2012;11(3):329-35. 48. Maxwell CA, Benítez J, Gómez-Baldó L, et al. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol. 2011;9(11):e1001199. 49. Rennert G. Bisphosphonates: beyond prevention of bone metastases. J Natl Cancer Inst. 2011;103(23):1728-9. 50. Sanz-Pamplona R, Cordero D, Berenguer A, Lejbkowicz F, Rennert H, Salazar R, Biondo S, Sanjuan X, Pujana MA, Rozek L, Giordano TJ, Ben-Izhak O, Cohen HI, Trougouboff P, Bejhar J, Sova Y, Rennert G, Gruber SB, Moreno V. Gene expression differences between colon and rectum tumors. Clin Cancer Res. 2011;17(23):7303-12. 51. Rennert G, Lejbkowicz F, Cohen I, Pinchev M, Rennert HS, Barnett-Griness O. MutYH mutation carriers have increased breast cancer risk. Cancer. 2012;118(8):1989-93. 52. Im KM, Kirchhoff T, Wang X, et al. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet. 2011;130(5):685-99. 53. Mukherjee B, Rennert G, Ahn J, Dishon S, Lejbkowicz F, Rennert HS, Shiovitz S, Moreno V, Gruber SB. High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation. Gastroenterology. 2011;140(7):1919-26. 54. Rennert G, Pinchev M, Rennert HS, Gruber SB. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol. 2011;29(9):1146-50.
55. Gaudet MM, Kirchhoff T, Green T, et al. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet. 2010;6(10):e1001183. 56. Antoniou AC, Beesley J, McGuffog L, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70(23):9742-54.57. Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, Rennert G. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. Ann Oncol. 2011;22(4):964-6. 58. Antoniou AC, Wang X, Fredericksen ZS, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010;42(10):885-92. 59. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010;28(22):3577-81. 60. Rennert G, Rennert HS, Pinchev M, Gruber SB. A case-control study of levothyroxine and the risk of colorectal cancer. J Natl Cancer Inst. 2010;102(8):568-72. 61. Osorio A, Milne RL, Pita G, et al. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br J Cancer 2009;101(12):2048-54. 62. Rennert G, Rennert HS, Pinchev M, Lavie O, Gruber SB. Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol. 2009;27(27):4542-7. 63. Antoniou AC, Sinilnikova OM, McGuffog L, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2009;18(22):4442-56. 64. Khoury-Shakour S, Lejbkowicz F, Barnett-Griness O, Tamir A, Pinchev M, Rennert G. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations. Eur J Cancer Prev 2009;18(5):361-7. 65. Raskin L, Lejbkowicz F, Barnett-Griness O, Dishon S, Almog R, Rennert G. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1617-23. 66. Khoury-Shakour S, Gruber SB, Lejbkowicz F, Rennert HS, Raskin L, Pinchev M, Rennert G. Recreational physical activity modifies the association between a common GH1 polymorphism and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3314-8. 67. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008;100(19):1361-7. 68. Lavie O, Gruber SB, Lejbkowicz F, Dishon S, Rennert G. Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation. Am J Obstet Gynecol. 2008;199(2):148.e1-3. 69. Raskin L, Pinchev M, Arad C, Lejbkowicz F, Tamir A, Rennert HS, Rennert G, Gruber SB. FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. Cancer Epidemiol Biomarkers Prev. 2008;17(5):1060-5.70. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357(2):115-23.71. Kotsopoulos J, Lubinski J, Lynch HT, et al. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2007;105(2):221-8. 72. Rennert G. Are we taking the right approach in planning chemoprevention studies? Nat Clin Pract Oncol 2006;3:464-5. 73. Rennert G, Dishon S, Rennert HS, Fares F. Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel. Eur J Cancer Prev. 2005;14(4):357-61. 74. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 2005;352(21):2184-92.75. Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchhoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Rennert G, Offit K. BLM heterozygosity and the risk of colorectal cancer. Science 2002;297(5589):2013.